CTC count as a biomarker for response to chemotherapy in men with mCRPC

There is increasing evidence that circulating tumor cell (CTC) count may be important in assessing the likelihood for an optimal response to treatment with docetaxel-based chemotherapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Two negatives don’t make a positive in patients with CRPC

Data from a small Phase II trial of cilengitide suggest that it  has minimal clinical effect in the treatment of men with non-metastatic, castration-resistant prostate cancer (CRPC). They also suggest that levels of circulating T-cells (CTCs) are of limited utility in monitoring the progression of this patient group. … READ MORE …